Cellectis S.A. (NASDAQ:CLLS) Sees Large Decline in Short Interest

Cellectis S.A. (NASDAQ:CLLS) was the recipient of a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 165,200 shares, a decline of 18.8% from the December 31st total of 203,500 shares. Based on an average daily volume of 139,000 shares, the days-to-cover ratio is currently 1.2 days.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Barclays dropped their target price on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th. StockNews.com assumed coverage on Cellectis in a research note on Friday, January 24th. They issued a “buy” rating on the stock.

Cellectis Stock Up 1.9 %

NASDAQ:CLLS traded up $0.03 during mid-day trading on Friday, reaching $1.61. The company’s stock had a trading volume of 65,036 shares, compared to its average volume of 224,277. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $89.48 million, a PE ratio of -1.24 and a beta of 3.08. The stock has a fifty day moving average of $1.76 and a 200-day moving average of $1.97. Cellectis has a 1 year low of $1.41 and a 1 year high of $3.38.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The business had revenue of $18.05 million during the quarter, compared to analysts’ expectations of $5.00 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. During the same period in the previous year, the company posted ($0.31) EPS. Equities research analysts forecast that Cellectis will post -0.46 earnings per share for the current year.

Institutional Trading of Cellectis

An institutional investor recently bought a new position in Cellectis stock. First Affirmative Financial Network bought a new stake in Cellectis S.A. (NASDAQ:CLLS) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 21,094 shares of the biotechnology company’s stock, valued at approximately $45,000. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.